Arrowhead Pharmaceuticals, Inc.
ARWR
$79.04
$1.301.67%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -72.07% | 2.95% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -72.07% | 2.95% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -72.07% | 2.95% | |||
| SG&A Expenses | -0.73% | 58.82% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -3.69% | 5.11% | |||
| Operating Income | -446.15% | -7.48% | |||
| Income Before Tax | -586.59% | -21.73% | |||
| Income Tax Expenses | -75.86% | -99.86% | |||
| Earnings from Continuing Operations | -587.12% | 75.19% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 88.40% | 106.44% | |||
| Net Income | -530.79% | 229.73% | |||
| EBIT | -446.15% | -7.48% | |||
| EBITDA | -385.79% | -6.52% | |||
| EPS Basic | -514.59% | 230.47% | |||
| Normalized Basic EPS | -542.18% | 217.78% | |||
| EPS Diluted | -523.64% | 226.36% | |||
| Normalized Diluted EPS | -554.17% | 214.67% | |||
| Average Basic Shares Outstanding | 3.92% | -0.61% | |||
| Average Diluted Shares Outstanding | 1.22% | 2.05% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||